Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
DOSIMETRY OF A D2 D3 DOPAMINE-RECEPTOR ANTAGONIST THAT CAN BE USED WITH PET OR SPECT/
Autore:
MOZLEY PD; STUBBS JB; KIM HJ; MCELGIN W; CHUMPRADIT S; KUNG MP; ROMANIELLO G; KUNG HF;
Indirizzi:
HOSP UNIV PENN,3400 SPRUCE ST,110 DONNER BLDG PHILADELPHIA PA 19104 UNIV PENN,MED CTR,DIV NUCL MED PHILADELPHIA PA 19104 OAK RIDGE INST SCI & EDUC,CTR RADIAT INTERNAL DOSE INFORMAT OAK RIDGETN 00000
Titolo Testata:
The Journal of nuclear medicine
fascicolo: 7, volume: 36, anno: 1995,
pagine: 1322 - 1331
SICI:
0161-5505(1995)36:7<1322:DOADDD>2.0.ZU;2-I
Fonte:
ISI
Lingua:
ENG
Soggetto:
POSITRON EMISSION TOMOGRAPHY; IMAGING AGENT; RAT-BRAIN; RADIOLIGAND; BIODISTRIBUTION; SCHIZOPHRENIA; OCCUPANCY; BINDING; INVITRO; POTENT;
Keywords:
FIDA-2; DOSIMETRY; DOPAMINE RECEPTOR; POSITRON EMISSION TOMOGRAPHY; SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
46
Recensione:
Indirizzi per estratti:
Citazione:
P.D. Mozley et al., "DOSIMETRY OF A D2 D3 DOPAMINE-RECEPTOR ANTAGONIST THAT CAN BE USED WITH PET OR SPECT/", The Journal of nuclear medicine, 36(7), 1995, pp. 1322-1331

Abstract

FIDA-2 hoxy-5-iodo-N-[(1-4'-fluorobenzyl)-2-pyrrolidinyl) methyl] benzamide) is a simultaneously fluorinated and iodinated D2/D3 dopamine receptor antagonist. The purpose of this study was to measure its biodistribution and radiation dosimetry in humans. Methods: Whole-body emission scans were sequentially acquired in eight healthy Volunteers 24-43 hr after the intravenous administration of 101-150 MBq I-123 FIDA-2. Regions of interest (ROIs) were placed on the initial set of conjugate emission images and transposed as a single set onto all the other scans without manipulating any of the regions for solid organs independently. The counts in each ROI were corrected for attenuation with transmission scans and compared to the net counts in images of the injection syringe containing the administered dose. The radiation doses were estimated with the MIRD formalism from the residence times for both theF-18- and I-123-labeled ligands. Results: There were no subjective orobjective pharmacological effects of the tracer on any of the subjects. The findings showed that the dose-limiting organ for the (123)-labeled product was the thyroid gland in this sample. If the F-18-labeled product had been used, then the urinary bladder would have received 0.086 mGy/MBq (0.32 rads/mCi) and become the dose-limiting organ. The effective dose equivalents were 0.025 mSv/MBq (0.092 rem/mCi) for both the I-123- and the F-18-labeled versions of the tracer. Conclusion: Thedata suggest that FIDA-2 can be used to produce relatively high contrast images of the D2/D3 dopaminergic system with substantially less than the maximum allowable radiation dose for research volunteers.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/01/20 alle ore 14:34:50